Following submission of new drug application of Zilretta (FX006) for knee osteoarthritis in mid-December 2016, Flexion Therapeutics CEO Mike Clayman is hoping for priority review of the filing, in addition to fast track status. Zilretta is an extended release formulation of the triamcinolone acetonide. Steroid injection is a common treatment, but pain relief wanes after two to four weeks. Competing against generic steroids, which cost only USD 10–20 per dose, presents a big commercial challenge however. In an interview at Biotech Showcase, Clayman explains the rationale for pricing a long-acting steroid at USD 500 per dose and the company's commercial strategy.
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
Our team is always happy to hear from you. Please call us at:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: